News Researchers start trial on AZ WEE1 drug in head and neck can... Phase 1 trial investigates use before and after surgery
News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News NICE okays CDF funding for BMS' Opdivo in head and neck canc... Cancer Drugs Fund will reimburse Opdivo for 2 years
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
